ANTONIO RAFAEL CÁLIZ CÁLIZ-rekin lankidetzan egindako argitalpenak (9)

2021

  1. Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts

    Frontiers in Immunology, Vol. 12

2020

  1. NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Correction: Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients (The Pharmacogenomics Journal, (2019), 19, 1, (83-96), 10.1038/s41397-018-0057-x)

    Pharmacogenomics Journal

  2. Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients

    Pharmacogenomics Journal, Vol. 19, Núm. 1, pp. 83-96

  3. Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium

    Scientific Reports, Vol. 9, Núm. 1

2015

  1. Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response: A two-stage case-control study

    Pharmacogenetics and Genomics, Vol. 25, Núm. 9, pp. 432-443

  2. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: A multicenter study

    Pharmacogenetics and Genomics, Vol. 25, Núm. 7, pp. 323-333

  3. TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy

    BioMed Research International, Vol. 2015

2013

  1. Gender-Specific Effects of Genetic Variants within Th1 and Th17 Cell-Mediated Immune Response Genes on the Risk of Developing Rheumatoid Arthritis

    PLoS ONE, Vol. 8, Núm. 8